Urological involvement by a non-Hodgkin lymphoma, once rare, is becoming more frequent. A clinical case is described where the urological onset was a volumetric increase in the lumbar-aortic lymph nodes and functional exclusion of the left kidney. Having ascertained the lymphomatous nature of the mass, chemotherapy cycles were carried out (CVP) and ureteral stenting to conserve renal function.
CohnheimJ.: Ein fall von Pseudoleukamie. Arch. Path. Anat., 33: 451, 1865.
2.
KwakL.W., LongoD.L.: Cancer chemotherapy and biological response modifiers. Annual 16. Editors: PinedoH.M., LongoD.L., ChabnerB.A.Elseiver Science B.V., 1996.
3.
MuirC., WaterhouseJ., MacktT., PowellJ., WhelanS.: Cancer incidence in five continents. Vol. V, I.A.R.C. Scientific Publication n. 8, Lyon 1987.
4.
ZanettiR., CrosignaniP.: Il cancro in Italia. I dati di incidenza dei Registri Tumori 1983–1987. Torino 1992.
5.
RiesL.HankeyB.F., MillerB.A., HartmanA.M., EdwardsB.K.: Cancer statistics review 1973–1988. National Cancer Institute NIH, 91: 2789, 1991.
6.
BiggarR.J., HormJ., GoedartJ.J., MelbyeM.: Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am. J. Epidemiol., 126: 578–586, 1987.
7.
SalemY.H., MillerH.C.: Lymphoma of genitourinary tract. J. Urol., 151: 1162–1170, 1994.
8.
WeimarG., CulpD.A., LoeningS., NarayanaA.: Urogenital involvement by malignant lymphoma, J. Urol., 125: 230, 1981.
9.
SharifkerD., ChalasaniA.: Ureteral involvement by malignant lymphoma; 10 years experience. Arch. Path. Lab. Med., 102: 54, 1978.
10.
MartinezM., Romirez deArellon G.: Renal involvement in malignant lymphoma. Amer. J. Med., 32: 184, 1962.
11.
TognoniP., BancheroR., RepettoU., CavigliaC.: Linfoma primitivo della prostata: un caso raro. Urologia, 62 (suppl. 1): 94–96, 1995.
DanaB.W., DahlbergS., NathawaniB.N.: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J. Clin. Urol., 11 (4): 644, 1993.
17.
ZuckermanK.S., CaseD.C.jr., GamsR.A., PrasthoferE.F.: Chemotherapy of intermediate and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen. Blood, 82: 3564–3573, 1993.
18.
MillsW., ChopraR., Mc MillanA., PearceR., LinchD.C., GoldstoneA.H.: Beam chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol., 13: 588–595, 1995.
19.
VoseJ.M., AndersonJ.R., KessingerA., BiermanP.J., CocciaP., ReedE.C., GordonB., ArmitageJ.O.: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J. Clin. Urol., 11: 1846–1851, 1993.
20.
WeberJ.S., YangJ.C., TopalianS.L.: The use of interleukin-2 and lymphokine actived killer cells for the treatment of patients with non-Hodgkin's lymphoma. J. Clin. Oncol., 1: 33, 1992.
21.
AndersonJ.W., SmalleyR.V.: Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up. N. Engl. J. Med., 329: 1821–1822, 1993.
